Clinical trial NCT06499922: Surgical Management of Low Grade Glioma
Official title: Recent Advances in Surgical Management of Low Grade Glioma
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Low Grade Glioma of Brain
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2024-07-15
Enrollment: 100
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Each patient will be subjected to:

* A complete history including personal history, history of seizures or drug intake.
* General clinical examination.
* Neurological examination.

Brief summary: To assess the morbidity and mortality in low grade glioma patients following surgical management.

Detailed description: lower-grade gliomas histological diagnosis has had a long history, each iteration of disease classification suffered from continued variability, with detrimental consequences on prognostic precision and treatment decision making.

In the WHO 2021 classification, there are three primary categories of adult-type diffuse gliomas: isocitrate dehydrogenase (IDH)-mutant, 1p/19q codeleted oligodendroglioma; IDH-mutant, non-codeleted astrocytoma; and IDH-wildtype glioblastoma. Diffuse low-grade glioma is classified as WHO grade 1 and 2 astrocytoma with IDH mutation or oligodendroglioma with IDH mutation and 1p/19q codeletion.

The presence of the IDH1 mutation has become a defining factor for adult diffuse low-grade glioma. Roughly 70% of grade 2-3 gliomas harbor mutations in either IDH1 or its mitochondrial counterpart IDH2.

Although lower-grade gliomas may present in various ways, the most common manifestation is seizures, and the development of seizures during the course of the disease may herald tumor progression. Among grade II tumors, the incidence of epilepsy is higher with IDH mutation. Anaplastic gliomas are somewhat less likely to manifest with seizures (57%) and are more likely than grade II gliomas to produce mental status, vision, and motor deficits.

Eligibility criteria: Inclusion Criteria:

* Patients diagnosed radiologically with low grade glioma

Exclusion Criteria:

* patients not fit for surgery

Primary outcomes:
measure: Morbidity in low grade glioma patients following surgical management.
timeFrame: 2 years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: professor
name: Ahmed El Gheriani, professor
role: STUDY_CHAIR
References:
citation: Davis ME. Epidemiology and Overview of Gliomas. Semin Oncol Nurs. 2018 Dec;34(5):420-429. doi: 10.1016/j.soncn.2018.10.001. Epub 2018 Nov 2.
citation: Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro Oncol. 2021 Aug 2;23(8):1231-1251. doi: 10.1093/neuonc/noab106.
citation: Mazzucchi E, La Rocca G, Ius T, Sabatino G, Della Pepa GM. Multimodality Imaging Techniques to Assist Surgery in Low-Grade Gliomas. World Neurosurg. 2020 Jan;133:423-425. doi: 10.1016/j.wneu.2019.10.120. No abstract available.